{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:10:14Z","timestamp":1794093014707,"version":"4.8.0"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vinney Foundation","award":["2022"],"award-info":[{"award-number":["2022"]}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01AI139141"],"award-info":[{"award-number":["5R01AI139141"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Proteasomes degrade intracellular proteins to generate antigenic peptides that are recognized by the adaptive immune system and promote anticancer immunity. However, tumors subvert the antigen presentation machinery to escape immunosurveillance. We hypothesized that proteasome activation could concomitantly increase antigen abundance and diversity in multiple myeloma cells. High-throughput screens revealed that histone deacetylase 6 (HDAC6) inhibitors activated proteasomes to unmask neoantigens and amplify the tumor-specific antigenic landscape. Treatment of patient CD138+ cells with HDAC6 inhibitors significantly promoted the antimyeloma activity of autologous CD8+ T cells. Pharmacologic blockade and genetic ablation of the HDAC6 ubiquitin-binding domain released HR23B, which shuttles ubiquitinylated cargo to proteasomes, while silencing HDAC6 or HR23B in multiple myeloma cells abolished the effect of HDAC6 inhibitors on proteasomes, antigen presentation, and T-cell cytotoxicity. Taken together, our results demonstrate the paradigm-shifting translational impact of proteasome activators to expand the myeloma immunopeptidome and have revealed novel, actionable antigenic targets for T cell\u2013directed immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The elimination of therapy-resistant tumor cells remains a major challenge in the treatment of multiple myeloma. Our study identifies and functionally validates agents that amplify MHC class I\u2013presented antigens and pave the way for the development of proteasome activators as immune adjuvants to enhance immunotherapeutic responses in patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0528","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:54:26Z","timestamp":1715763266000},"page":"1517-1532","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-4383","authenticated-orcid":true,"given":"Priyanka S.","family":"Rana","sequence":"first","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"2Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-2655","authenticated-orcid":true,"given":"James J.","family":"Ignatz-Hoover","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"2Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8921-5061","authenticated-orcid":true,"given":"Byung-Gyu","family":"Kim","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"2Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-4327","authenticated-orcid":true,"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"2Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"3Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-8341","authenticated-orcid":true,"given":"Yuriy","family":"Federov","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"4Small Molecule Drug Discovery Core, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3038-336X","authenticated-orcid":true,"given":"Drew","family":"Adams","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"4Small Molecule Drug Discovery Core, Case Western Reserve University, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-0283","authenticated-orcid":true,"given":"Timothy","family":"Chan","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"5Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-0617","authenticated-orcid":true,"given":"James J.","family":"Driscoll","sequence":"additional","affiliation":[{"name":"1Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"2Division of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, Ohio."},{"name":"3Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"2024062014135400200_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"2024062014135400200_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","article-title":"Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations","volume":"136","author":"Mikhael","year":"2023","journal-title":"Am J Med"},{"key":"2024062014135400200_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"2024062014135400200_bib4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"2024062014135400200_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and function of the 26S proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"2024062014135400200_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 \u212b resolution","volume":"268","author":"L\u00f6we","year":"1995","journal-title":"Science"},{"key":"2024062014135400200_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tibs.2015.10.009","article-title":"Gates, Channels, and switches: elements of the proteasome machine","volume":"41","author":"Finley","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"2024062014135400200_bib8","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1016\/S0021-9258(19)34041-4","article-title":"The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins","volume":"286","author":"Driscoll","year":"1990","journal-title":"J Biol Chem"},{"key":"2024062014135400200_bib9","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1128\/MCB.22.13.4902-4913.2002","article-title":"Rad23 promotes the targeting of proteolytic substrates to the proteasome","volume":"22","author":"Chen","year":"2002","journal-title":"Mol Cell Biol"},{"key":"2024062014135400200_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.molcel.2009.11.012","article-title":"Rpn10 and Dsk2 can serve as a polyubiquitin chain-length sensor","volume":"36","author":"Zhang","year":"2009","journal-title":"Mol Cell"},{"key":"2024062014135400200_bib11","doi-asserted-by":"crossref","first-page":"16310","DOI":"10.1074\/jbc.M117.803619","article-title":"The proteasome-interacting Ecm29 protein disassembles the 26S proteasome in response to oxidative stress","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"2024062014135400200_bib12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00018-011-0657-y","article-title":"The role of the proteasome in the generation of MHC class I ligands and immune responses","volume":"68","author":"Sijts","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"2024062014135400200_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3389\/fonc.2019.00761","article-title":"Proteasomes and several aspects of their heterogeneity relevant to cancer","volume":"9","author":"Morozov","year":"2019","journal-title":"Front Oncol"},{"key":"2024062014135400200_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"2024062014135400200_bib15","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-020-14639-9","article-title":"Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma","volume":"11","author":"Kalaora","year":"2020","journal-title":"Nat Commun"},{"key":"2024062014135400200_bib16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell"},{"key":"2024062014135400200_bib17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2024062014135400200_bib18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024062014135400200_bib19","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.chembiol.2017.05.010","article-title":"Proteasome activation by small molecules","volume":"24","author":"Leestemaker","year":"2017","journal-title":"Cell Chem Biol"},{"key":"2024062014135400200_bib20","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1021\/acs.jmedchem.9b00101","article-title":"Proteasome activation as a new therapeutic approach to target proteotoxic disorders","volume":"62","author":"Njomen","year":"2019","journal-title":"J Med Chem"},{"key":"2024062014135400200_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/acscombsci.7b00193","article-title":"Development and application of a sensitive peptide reporter to discover 20S proteasome stimulators","volume":"20","author":"Coleman","year":"2018","journal-title":"ACS Comb Sci"},{"key":"2024062014135400200_bib22","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3390\/molecules24122341","article-title":"Methods to discover and evaluate proteasome small molecule stimulators","volume":"25","author":"Coleman","year":"2019","journal-title":"Molecules"},{"key":"2024062014135400200_bib23","first-page":"4827","article-title":"Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines","volume":"48","author":"Scudiero","year":"1988","journal-title":"Cancer Res"},{"key":"2024062014135400200_bib24","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"2024062014135400200_bib25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","article-title":"Introduction of soluble protein into the class I pathway of antigen processing and presentation","volume":"54","author":"Moore","year":"1988","journal-title":"Cell"},{"key":"2024062014135400200_bib26","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.4049\/jimmunol.152.8.3884","article-title":"Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides","volume":"152","author":"Dick","year":"1994","journal-title":"J Immunol"},{"key":"2024062014135400200_bib27","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1073\/pnas.89.13.6020","article-title":"Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens","volume":"89","author":"Karttunen","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024062014135400200_bib28","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.8b00258","article-title":"Identification and structure-activity relationship of HDAC6 zinc-finger ubiquitin binding domain inhibitors","volume":"61","author":"Ferreira de Freitas","year":"2018","journal-title":"J Med Chem"},{"key":"2024062014135400200_bib29","doi-asserted-by":"crossref","first-page":"Abstract nr 577","DOI":"10.1158\/1538-7445.AM2019-577","article-title":"Optimization of methods for the analysis of class I MHC peptides by mass spectrometry [abstract]","volume":"79","author":"Ford","year":"2019","journal-title":"Cancer Res"},{"key":"2024062014135400200_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2024062014135400200_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2024062014135400200_bib32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/cdd.2013.47","article-title":"A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors","volume":"20","author":"New","year":"2013","journal-title":"Cell Death Differ"},{"key":"2024062014135400200_bib33","doi-asserted-by":"crossref","first-page":"E11642","DOI":"10.1073\/pnas.1808731115","article-title":"UBL domain of Usp14 and other proteins stimulates proteasome activities and protein degradation in cells","volume":"115","author":"Kim","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024062014135400200_bib34","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1073\/pnas.1915534117","article-title":"Proteins containing ubiquitin-like (Ubl) domains not only bind to 26S proteasomes but also induce their activation","volume":"117","author":"Collins","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024062014135400200_bib35","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1073\/pnas.0913912107","article-title":"HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy","volume":"107","author":"Khan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024062014135400200_bib36","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1128\/MCB.22.13.4902-4913.2002","article-title":"Rad23 promotes the targeting of proteolytic substrates to the proteasome","volume":"22","author":"Chen","year":"2002","journal-title":"Mol Cell Biol"},{"key":"2024062014135400200_bib37","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024062014135400200_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2010.02.010","article-title":"Histone deacetylases and epigenetic therapies of hematological malignancies","volume":"62","author":"Mercurio","year":"2010","journal-title":"Pharmacol Res"},{"key":"2024062014135400200_bib39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","article-title":"Essential role of HDAC6 in the regulation of PD-L1 in melanoma","volume":"10","author":"Lienlaf","year":"2016","journal-title":"Mol Oncol"},{"key":"2024062014135400200_bib40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00280-018-3721-6","article-title":"Role of the hdac6\/stat3 pathway in regulating pd-l1 expression in osteosarcoma cell lines","volume":"83","author":"Keremu","year":"2019","journal-title":"Cancer Chemother Pharm"},{"key":"2024062014135400200_bib41","first-page":"3311","article-title":"Histone deacetylase 6 (hdac6) as a regulator of immune check-point molecules in chronic lymphocytic leukemia (cll)","volume":"124","author":"Powers","year":"2014","journal-title":"Blood Cancer J"},{"key":"2024062014135400200_bib42","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Sci Rep"},{"key":"2024062014135400200_bib43","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"2024062014135400200_bib44","doi-asserted-by":"crossref","first-page":"696512","DOI":"10.3389\/fonc.2021.696512","article-title":"Selective histone deacetylase inhibitor ACY-241 (citarinostat) plus nivolumab in advanced non-small cell lung cancer: results from a phase Ib study","volume":"11","author":"Awad","year":"2021","journal-title":"Front Oncol"},{"key":"2024062014135400200_bib45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","article-title":"The anti-melanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity","volume":"23","author":"Woods","year":"2013","journal-title":"Melanoma Res"},{"key":"2024062014135400200_bib46","first-page":"499","article-title":"HDAC6selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma","volume":"55","author":"Won","year":"2019","journal-title":"Int J Oncol"},{"key":"2024062014135400200_bib47","doi-asserted-by":"crossref","first-page":"606368","DOI":"10.3389\/fonc.2020.606368","article-title":"Harnessing the immune system against multiple myeloma: challenges and opportunities","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Front Oncol"},{"key":"2024062014135400200_bib48","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024062014135400200_bib49","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/ijms24021231","article-title":"A new potential therapeutic target for cancer in ubiquitin-like proteins-UBL3","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024062014135400200_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin\u2013proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2024062014135400200_bib51","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.3390\/ijms23095053","article-title":"Ubiquitin and ubiquitin-like proteins in cancer, neurodegenerative disorders, and heart diseases","volume":"23","author":"Hwang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024062014135400200_bib52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2024062014135400200_bib53","doi-asserted-by":"crossref","first-page":"850358","DOI":"10.3389\/fimmu.2022.850358","article-title":"Emerging strategies in TCR-engineered T cells","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0528\/3453404\/crc-23-0528.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/6\/1517\/3464162\/crc-23-0528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/6\/1517\/3464162\/crc-23-0528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:15:06Z","timestamp":1718878506000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/6\/1517\/745958\/HDAC6-Inhibition-Releases-HR23B-to-Activate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,18]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0528","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.26058227.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058161.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058161","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058173","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058209.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058185","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058197","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058242","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058242.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058245.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058248.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058167.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058179.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058257.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058191.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058185.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058182.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058170","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058182","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058176.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058194","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058254.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058158","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058203","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058194.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058251","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058197.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058188.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058239","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058158.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058236.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058233.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058230.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058191","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058167","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058239.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058200","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058179","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058173.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058236","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058170.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058251.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058248","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058203.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058200.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058206.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058212.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058245","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058215.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058233","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058221.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058176","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058188","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058218.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.26058224.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7291364.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7291364","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}